CINC News and Press, CinCor Pharma Inc. From 08/08/22

CinCor Pharma ( NASDAQ: CINC ) on Monday announced an underwritten public offering of 6M shares . CINC may, in lieu of stock, offer and sell to certain investors pre-funded warrants to buy shares in the offering. The firm intends to grant underwriters a 30-day opt...

WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat, for the treatment of hypertension and other cardio-renal diseases, today a...

Gainers: CinCor Pharma CINC +66% . Karuna Therapeutics KRTX +61% . 23andMe ( ME ) +22% . Cerevel Therapeutics ( CERE ) +20% . Quoin Pharmaceuticals ( QNRX ) +16% . Losers: Reata Pharmaceuticals RETA -31% . uniQure QUR...

CinCor Pharma press release ( NASDAQ: CINC ): Q2 GAAP EPS of -$0.56 misses by $0.08 . Cash, cash equivalents and marketable securities totaled $294.3 million as of June 30, 2022, as compared to $136.6 million as of December 31, 2021. Shares +28% PM For fu...

CinCor Pharma ( NASDAQ: CINC ) shares climbed ~13% in the pre-market Monday after the cardio-renal drug developer said that its Phase 2 trial for lead asset baxdrostat met the primary endpoint in patients with treatment-resistant hypertension. The company limited the enr...

Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension Completed enrollment in the HALO Phase 2 trial for baxdrostat in patients with unco...

Successfully met the primary endpoint in the BrigHtn trial, delivering a 20.3 mmHg reduction in systolic blood pressure (SBP), or an 11 mmHg (p-value < 0.0001) decline on a placebo-adjusted basis, at 2 mg dose Independent Data Review Committee determined that the trial met pr...

CinCor Pharma ( NASDAQ: CINC ) said the last patient had been randomized in the Phase 2 trial of baxdrostat to treat patients with uncontrolled hypertension. The company also said it had an open-label extension study of patients enrolled in the Phase 2 trial, dubbed Ha...

Open Label Extension Study Will Evaluate Baxdrostat for Up to 52 Weeks Topline Data for Phase 2 HALO Trial Expected in 2H 2022 Topline Data for Phase 2 BrigHtn Trial Expected in August 2022 WALTHAM, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...